In summary, molecular analyses of cancer tissue obtained from six ER-positive, HER2-negative MBC patients who had exceptional responses to capecitabine suggest that functional alterations in DNA-damage-response and chromatin remodeling genes may predict for prolonged response to capecitabine within this phenotypic context. The gene discussed is ERBB2; the disease is cancer.